ClinicalTrials.gg
CompletedNCT03387852Updated Jun 14, 2022Results posted

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

A Phase 2 interventional study of SAR440340 and Dupilumab in Asthma, sponsored by Sanofi. Completed at 71 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
23rd of 31
296 · median 450
Started
2018
with 2 others
Phase 2
11 of 37
1 open now
Registered
17th of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 in phase 2, and was the 17th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.

Secondary Objectives:

To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340 and dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1).

To evaluate the effects of coadministration of SAR440340 and dupilumab, compared with SAR440340 and compared with dupilumab, on FEV1.

To assess safety and tolerability of SAR440340 alone and in coadministration with dupilumab.

Read the detailed description

The total duration of the study (per participant) was approximately 36 weeks, including 4 weeks screening, 12 weeks treatment, and 20 weeks post-treatment.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with a physician diagnosis of asthma for at least 12 months based on the Global Initiative for Asthma (GINA) 2017 Guidelines.
  • Participants with existing treatment with medium to high dose ICS (greater than or equal to [>=] 250 microgram (mcg) of fluticasone propionate twice a day (BID) or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or clinically comparable) in combination with a LABA as second controller for at least 3 months with a stable dose >=1 month prior to Visit 1.
  • Participants with pre-bronchodilator greater than (>) 40 percent (%) of predicted normal at Visit 1/Screening. Pre-bronchodilator FEV1 >=50% but less than or equal to (\<=) 85% of predicted normal at Visit 2/Baseline.
  • Participants with reversibility of at least 12% and 200 milliliters (mL) in FEV1 after administration of 2 to 4 puffs (200-400 microgram [µg]) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criteria within 12 months prior to Visit 1 or documented positive response to methacholine challenge (a decrease in FEV by 20% [PC20] of less than [\<] 8 milligram per milliliter [mg/mL]) within 12 months prior to Visit 1/Screening is considered acceptable to meet this inclusion criterion.
  • Participants had experienced, within 1 year prior to Visit 1, any of the following events at least once:
  • Treatment with a systemic (oral or parenteral) for worsening asthma.
  • Hospitalization or emergency medical care visit for worsening asthma.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Participants \<18 years or >70 years of age (i.e., have reached the age of 71 at the screening visit).
  • Participants with (BMI) \<16.
  • Chronic lung disease (for example, [COPD], or idiopathic pulmonary fibrosis [IPF]), which might impair lung function.
  • History of life threatening asthma (i.e., severe exacerbation that required intubation).
  • Co-morbid disease that might interfere with the evaluation of medicinal product (IMP).
  • Participants with any of the following events within the 4 weeks prior to their Screening Visit 1:
  • Treatment with 1 or more systemic (oral and/or parenteral) bursts for worsening asthma;
  • Hospitalization or emergency medical care visit for worsening asthma.
  • Asthma Control Questionnaire 5-question version (ACQ-5) score \<1.25 or >3.0 at Visit 2/randomization. During the screening period, an ACQ-5 of up to \<=4 was acceptable.
  • Anti-immunoglobulin E (IgE) therapy (e.g., omalizumab [Xolair®]) within 130 days prior to Visit 1 or any other biologic therapy (including anti interleukin-5 [anti-IL5] monoclonal antibodies [mAb]) or systemic (e.g., methotrexate) to treat inflammatory disease or disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever was longer.
  • Participants with a history of a systemic reaction to a biologic drug.
  • Participants on or initiation of bronchial thermoplasty within 2 years prior to Visit 1 or plan to begin therapy during the screening period or the randomized treatment period.
  • Current smoker or cessation of smoking within the 6 months prior to Visit 1.
  • Previous smoker with a smoking history >10 pack-years.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    SAR440340

    Participants received 2 injections of SAR440340 300 milligram (mg) along with 1 injection of dupilumab placebo, subcutaneous (SC) once every 2 weeks (Q2W) for 12 weeks.

    Drug: SAR440340 · Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for dupilumab

  • Active comparator
    Dupilumab

    Participants received 1 injection of dupilumab 300 mg along with 2 injections of SAR440340 placebo, SC Q2W for 12 weeks.

    Drug: Dupilumab · Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for SAR440340

  • Experimental
    SAR440340 + Dupilumab

    Participants received 2 injections of SAR440340 300 mg along with 1 injection of dupilumab 300 mg, SC Q2W for 12 weeks.

    Drug: SAR440340 · Drug: Dupilumab · Drug: Fluticasone or Fluticasone/salmeterol combination

  • Placebo comparator
    Placebo

    Participants received 2 SC injections of SAR440340 placebo along with 1 SC injection of dupilumab placebo Q2W for 12 weeks.

    Drug: Fluticasone or Fluticasone/salmeterol combination · Drug: Placebo for SAR440340 · Drug: Placebo for dupilumab

Interventions

  • Pharmaceutical form: Solution for Injection, Route of administration: SC

    Also known as: REGN3500

  • Pharmaceutical form: Solution for Injection, Route of administration: SC

    Also known as: SAR231893 (REGN668)

  • DrugFluticasone or Fluticasone/salmeterol combination

    Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled

  • DrugPlacebo for SAR440340

    Pharmaceutical form: Solution for Injection, Route of administration: SC

  • DrugPlacebo for dupilumab

    Pharmaceutical form: Solution for Injection, Route of administration: SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Loss of Asthma Control

    An LOAC event during the 12-week treatment period was a deterioration of asthma defined as any of the following: a) 30 percent (%) or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; b) greater than or equal to (\>=) 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; c) increase in inhaled corticosteroid (ICS) \>=4 times the last prescribed ICS dose (or \>=50% of the prescribed ICS dose at Baseline if background therapy withdrawal completed); d) required use of systemic (oral and/or parenteral) steroid treatment; e) required hospitalization or emergency room visit.

    Time frame: From Baseline up to Week 12

Secondary outcomes

  1. Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Pre-bronchodilator FEV1 refers to the spirometry performed after a wash period of bronchodilators (i.e., not earlier than 6 hours) after the last dose of albuterol/salbutamol or levalbuterol/levosalbutamol from a primed meter dose inhaler and withholding the last dose of long-acting β2 adrenergic agonist (LABA) for at least 12 hours, and prior to administration of study drug.

    Time frame: Baseline, Week 12

  2. Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 refers to the spirometry performed within 30 minutes after administration of bronchodilator.

    Time frame: Baseline, Week 12

07

Results

Posted Mar 29, 2022

Participant flow

The study was conducted from 12-March-2018 to 7-August-2019. Participants were screened at 70 centers across 8 countries, out of which 68 centers randomized at least 1 participant.

Participant flow — Overall Study
MilestonePlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mg
Started74737475
Treated74737474
Completed41554756
Not completed33182719
Withdrew: Adverse event (ae)3020
Withdrew: Loss of asthma control (loac)28162014
Withdrew: Withdrawal by participant1132
Withdrew: Other- unspecified1121
Withdrew: Poor compliance to protocol0001
Withdrew: Randomized and not treated0001

Outcome measures

PrimaryPercentage of Participants With Loss of Asthma Control

An LOAC event during the 12-week treatment period was a deterioration of asthma defined as any of the following: a) 30 percent (%) or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; b) greater than or equal to (\>=) 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; c) increase in inhaled corticosteroid (ICS) \>=4 times the last prescribed ICS dose (or \>=50% of the prescribed ICS dose at Baseline if background therapy withdrawal completed); d) required use of systemic (oral and/or parenteral) steroid treatment; e) required hospitalization or emergency room visit.

Time frame:
From Baseline up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of Asthma Control
percentage of participantsPlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mg
Percentage of Participants With Loss of Asthma Control40.521.927.018.9
Statistical analysis
  • Placebo vs SAR440340 300 mg · Regression, Logistic · p = =0.0214 · Odds ratio: 0.423 · 95% CI 0.203 to 0.88SAR440340 300 mg vs. Placebo
  • Placebo vs SAR440340 + Dupilumab · Regression, Logistic · p = =0.0709 · Odds ratio: 0.520 · 95% CI 0.256 to 1.057SAR440340 + Dupilumab vs. Placebo
SecondaryChange From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Pre-bronchodilator FEV1 refers to the spirometry performed after a wash period of bronchodilators (i.e., not earlier than 6 hours) after the last dose of albuterol/salbutamol or levalbuterol/levosalbutamol from a primed meter dose inhaler and withholding the last dose of long-acting β2 adrenergic agonist (LABA) for at least 12 hours, and prior to administration of study drug.

Time frame:
Baseline, Week 12
Reported as:
Mean · liters
Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
litersPlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mg
Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)0.06 ± 0.350.11 ± 0.340.06 ± 0.370.14 ± 0.43
SecondaryChange From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 refers to the spirometry performed within 30 minutes after administration of bronchodilator.

Time frame:
Baseline, Week 12
Reported as:
Mean · liters
Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second
litersPlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mg
Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second-0.02 ± 0.27-0.00 ± 0.330.06 ± 0.410.09 ± 0.42

Adverse events

Collected over From first administration of IMP up to the final visit (Week 32) regardless of seriousness or relationship to IMP. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/74 (0%)3/74 (4.1%)31/74 (41.9%)
SAR440340 300mg0/73 (0%)3/73 (4.1%)29/73 (39.7%)
SAR440340 + Dupilumab0/74 (0%)2/74 (2.7%)26/74 (35.1%)
Dupilumab 300mg1/74 (1.4%)3/74 (4.1%)28/74 (37.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboSAR440340 300mgSAR440340 + DupilumabDupilumab 300mg
PneumoniaInfections and infestations0/741/730/740/74
AsthmaRespiratory, thoracic and mediastinal disorders0/741/730/740/74
Deep Vein ThrombosisVascular disorders0/741/730/740/74
Aortic Valve IncompetenceCardiac disorders0/740/730/741/74
Cholecystitis AcuteHepatobiliary disorders1/740/730/740/74
Abscess JawInfections and infestations0/740/730/741/74
Pyelonephritis AcuteInfections and infestations0/740/731/740/74
Alcohol PoisoningInjury, poisoning and procedural complications0/740/730/741/74
Alanine Aminotransferase IncreasedInvestigations0/740/731/740/74
Vascular EncephalopathyNervous system disorders1/740/730/740/74
Most frequent other events
Most frequent other events
EventPlaceboSAR440340 300mgSAR440340 + DupilumabDupilumab 300mg
NasopharyngitisInfections and infestations9/7413/738/749/74
HeadacheNervous system disorders7/746/735/7410/74
Injection Site ReactionGeneral disorders4/741/735/744/74
Urinary Tract InfectionInfections and infestations2/741/735/743/74
Viral Upper Respiratory Tract InfectionInfections and infestations5/743/735/742/74
CoughRespiratory, thoracic and mediastinal disorders5/741/730/741/74
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders1/743/730/745/74
NauseaGastrointestinal disorders2/744/732/741/74
Back PainMusculoskeletal and connective tissue disorders1/744/732/743/74
Upper Respiratory Tract Infection BacterialInfections and infestations2/741/734/742/74

Baseline characteristics

Analysis was performed on randomized population that included any participant who had signed informed consent and had been allocated to a randomized treatment regardless of whether the treatment kit was used.

Age, Continuous
Age, Continuous(years)PlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mgTotal
Mean47.0 ± 11.449.0 ± 13.949.1 ± 12.051.3 ± 12.749.1 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mgTotal
Female47505141189
Male27232334107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSAR440340 300 mgSAR440340 + DupilumabDupilumab 300 mgTotal
American Indian or Alaska Native20114
Asian02114
Native Hawaiian or Other Pacific Islander00000
Black or African American13206
White71686973281
More than one race00101
Unknown or Not Reported00000
08

Study locations

71 sites
  • Investigational Site Number 8400026
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 8400004
    Long Beach, California 90808, United States
  • Investigational Site Number 8400020
    Los Angeles, California 90025, United States
  • Investigational Site Number 8400001
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 8400013
    San Jose, California 95117, United States
  • Investigational Site Number 8400009
    Stockton, California 95207, United States
  • Investigational Site Number 8400016
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number 8400021
    Ann Arbor, Michigan 48109, United States
  • Investigational Site Number 8400022
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 8400007
    Papillion, Nebraska 27103, United States
  • Investigational Site Number 8400025
    Edmond, Oklahoma 73034, United States
  • Investigational Site Number 8400011
    Medford, Oregon 97504, United States
  • Investigational Site Number 8400024
    Portland, Oregon 97209, United States
  • Investigational Site Number 8400010
    Dallas, Texas 75231, United States
  • Investigational Site Number 8400023
    Dallas, Texas 75231, United States
  • Investigational Site Number 8400006
    Plano, Texas 75093, United States
  • Investigational Site Number 8400008
    Murray, Utah 84107, United States
  • Investigational Site Number 8400014
    Milwaukee, Wisconsin 53219, United States
  • Investigational Site Number 0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number 0320003
    Caba, C1122AAK, Argentina
  • Investigational Site Number 0320002
    Caba, C1425BEN, Argentina
  • Investigational Site Number 0320004
    Caba, C1425FVH, Argentina
  • Investigational Site Number 0320005
    Mendoza, 5500, Argentina
  • Investigational Site Number 1520002
    Quillota, 2260877, Chile
  • Investigational Site Number 1520001
    Santiago, 7500692, Chile
  • Investigational Site Number 1520009
    Santiago, 7500710, Chile
  • Investigational Site Number 1520008
    Santiago, 8207257, Chile
  • Investigational Site Number 1520007
    Santiago, 8330336, Chile
  • Investigational Site Number 1520004
    Santiago, 8910131, Chile
  • Investigational Site Number 1520005
    Talca, Chile
  • Investigational Site Number 1520003
    Viña Del Mar, Chile
  • Investigational Site Number 4840005
    Chihuahua, 31000, Mexico
  • Investigational Site Number 4840004
    Durango, 34080, Mexico
  • Investigational Site Number 4840002
    Guadalajara, 44100, Mexico
  • Investigational Site Number 4840006
    Monterrey, 64460, Mexico
  • Investigational Site Number 4840001
    Monterrey, 66465, Mexico
  • Investigational Site Number 4840003
    Veracruz, 91910, Mexico
  • Investigational Site Number 6160001
    Bialystok, 15-010, Poland
  • Investigational Site Number 6160008
    Bialystok, 15-044, Poland
  • Investigational Site Number 6160005
    Bydgoszcz, 85-079, Poland
  • Investigational Site Number 6160007
    Krakow, 31-559, Poland
  • Investigational Site Number 6160002
    Poznan, 60-693, Poland
  • Investigational Site Number 6160006
    Poznan, 60-823, Poland
  • Investigational Site Number 6160003
    Znin, 88-400, Poland
  • Investigational Site Number 6430003
    Moscow, 109240, Russian Federation
  • Investigational Site Number 6430001
    Moscow, 109544, Russian Federation
  • Investigational Site Number 6430005
    Moscow, 115280, Russian Federation
  • Investigational Site Number 6430008
    Ryazan, 390039, Russian Federation
  • Investigational Site Number 6430010
    Saint-Petersburg, 194291, Russian Federation
  • Investigational Site Number 6430006
    Saint-Petersburg, 194354, Russian Federation
  • Investigational Site Number 6430007
    St-Petersburg, 193231, Russian Federation
  • Investigational Site Number 6430009
    Stavropol, 355030, Russian Federation
  • Investigational Site Number 6430004
    Ulyanovsk, 432017, Russian Federation
  • Investigational Site Number 7920004
    Ankara, 06100, Turkey
  • Investigational Site Number 7920003
    Bursa, 16059, Turkey
  • Investigational Site Number 7920001
    Istanbul, 34098, Turkey
  • Investigational Site Number 7920006
    Izmir, 35040, Turkey
  • Investigational Site Number 7920007
    Izmir, 35110, Turkey
  • Investigational Site Number 7920008
    Kirikkale, 71450, Turkey
  • Investigational Site Number 7920002
    Mersin, 33070, Turkey
  • Investigational Site Number 7920009
    Rize, 53100, Turkey
  • Investigational Site Number 8040008
    Chernivtsi, 58001, Ukraine
  • Investigational Site Number 8040012
    Ivano-Frankivsk, 76000, Ukraine
  • Investigational Site Number 8040002
    Kharkiv, 61039, Ukraine
  • Investigational Site Number 8040009
    Kharkiv, 61124, Ukraine
  • Investigational Site Number 8040011
    Kharkiv, 61166, Ukraine
  • Investigational Site Number 8040007
    Kyiv, 02091, Ukraine
  • Investigational Site Number 8040001
    Kyiv, 02125, Ukraine
  • Investigational Site Number 8040006
    Odesa, 65025, Ukraine
  • Investigational Site Number 8040003
    Ternopil, 46000, Ukraine
  • Investigational Site Number 8040005
    Vinnytsya, 21001, Ukraine
09

References and documents

Publications

  • Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. doi: 10.1056/NEJMoa2024257. PubMed 34706171 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Mar 2019, 12 months.

Results were first posted in Mar 2022, 3 years after primary completion. A results delay was requested in May 2020.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Jan 2, 2018
StartActual
Mar 12, 2018
Primary completionActual
Mar 21, 2019
CompletionActual
Aug 7, 2019
Results delay requested
May 6, 2020
Results first posted
Mar 29, 2022
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03387852
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 2, 2018
Start date
Mar 12, 2018
Primary completion
Mar 21, 2019
Completion
Aug 7, 2019
Results posted
Mar 29, 2022
Last update
Jun 14, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion